Getting IVIG covered by insurance requires a combination of the right diagnosis documentation, a strong prior authorization submission, and persistence through denials if they happen. IVIG typically costs $10,000 to $30,000 or more per infusion, so insurance coverage is essential for most patients. The process is navigable, but it demands specific paperwork, lab results, and sometimes multiple rounds of appeals.
Conditions Most Likely to Get Approved
Your chances of getting IVIG covered depend heavily on your diagnosis. Insurers divide IVIG uses into two categories: FDA-approved indications and off-label uses. FDA-approved conditions get the smoothest path to approval. These include primary immune deficiency diseases, chronic inflammatory demyelinating polyneuropathy (CIDP), immune thrombocytopenia, Guillain-Barré syndrome, myasthenia gravis, and certain autoimmune blistering skin diseases.
For primary immune deficiency specifically, Medicare and most private insurers have well-established coverage pathways. CMS maintains a list of more than 25 qualifying diagnosis codes, covering conditions like common variable immunodeficiency, severe combined immunodeficiency, selective IgG subclass deficiency, Wiskott-Aldrich syndrome, and DiGeorge syndrome. If your diagnosis falls on this list, prior authorization is more straightforward.
Off-label uses, such as for multiple sclerosis, polymyositis, dermatomyositis, or Lambert-Eaton myasthenic syndrome, face more scrutiny. Insurers evaluate off-label requests against recognized medical references including AHFS Drug Information, Clinical Pharmacology, Lexi-Drugs, Micromedex DrugDex, and the National Comprehensive Cancer Network guidelines. If your condition is listed in one of these compendia as a supported use for IVIG, your insurer is more likely to approve it. Your doctor should reference the specific compendium entry in the authorization request.
What Your Doctor Needs to Submit
Nearly all private insurance plans and Medicare require prior authorization before IVIG treatment begins. The authorization request is only as strong as the documentation behind it, and incomplete submissions are a common reason for delays or denials. Here is what should be included:
- Copies of your insurance cards (front and back), including any separate prescription benefit cards.
- The prior authorization form from your specific insurance plan.
- Medical records with your initial history, physical exam, and the ICD-10 diagnosis code for your condition.
- Lab results supporting the diagnosis. For immune deficiency, this means pre-treatment IgG, IgA, and IgM levels drawn on two separate occasions. For conditions like immune thrombocytopenia, a platelet count from the past 30 days is required. For CIDP, electrodiagnostic nerve conduction studies must show specific patterns of nerve damage.
- Vaccine response testing when applicable, including the dates vaccines were given and the pre- and post-vaccination antibody levels showing your body failed to respond normally.
- Documentation of failed alternatives. Many insurers require proof that you tried other treatments first. For autoimmune blistering diseases, that means steroids and immunosuppressants. For Lambert-Eaton syndrome, it means at least one immunomodulator. For relapsing multiple sclerosis, you may need to have failed at least two disease-modifying therapies.
- A letter of medical necessity from your prescribing doctor.
- Procedure and billing codes (CPT or J codes) for the infusion.
UnitedHealthcare’s policy, which is representative of many large insurers, also requires your doctor to attest that dosing follows FDA-approved labeling or is supported by published clinical evidence. Progress notes from the past six months and a clear treatment plan should be part of the package.
Writing a Strong Letter of Medical Necessity
The letter of medical necessity is often the most important single document in the prior authorization. A vague or incomplete letter is one of the easiest things for an insurer to reject. The Immune Deficiency Foundation recommends the letter include your full name, insurance ID number, date of birth, specific IVIG product and dosage prescribed, ICD-10 diagnosis code, the medical history justifying the need for treatment, any reasons a particular brand or route of administration is required, and your doctor’s contact information.
Beyond the basics, the letter should tell a clinical story. It should explain what symptoms you experience, what other treatments were tried and why they failed or aren’t appropriate, what objective test results support the diagnosis, and what the expected outcome of IVIG treatment is. If your use is off-label, the letter should cite the specific compendium or peer-reviewed studies supporting IVIG for your condition. The more specific and evidence-based this letter is, the harder it becomes for a reviewer to deny.
What to Do When You Get Denied
Denials are common with IVIG, but they are not the end of the road. Under federal law, you have the right to a written explanation of why your claim was denied. If you didn’t receive a denial letter, request one. The letter will contain a specific reason for the denial, which tells you exactly what you need to address in your appeal.
The appeal process typically follows three stages. First, request a peer-to-peer review where your doctor speaks directly with the insurance company’s reviewing physician. This is often the fastest way to resolve a denial, because your doctor can explain the clinical reasoning in a way that written records sometimes don’t convey. Many denials are overturned at this stage.
If the peer-to-peer review doesn’t work, you file a formal written appeal. A strong appeal letter should include your name, policy number, claim number, date of denial, a clear statement that you’re appealing, an explanation of why the treatment is medically necessary, citations from your insurance policy language that support coverage, and all supporting documents: the denial letter, medical records, test results, documentation of failed alternative therapies, and your doctor’s letter of medical necessity. Point out specific sections of your policy that apply to your situation.
If the internal appeal is denied, you have the right to request an independent external review. This is conducted by a third party not employed by your insurance company. You can also file a complaint with your state insurance commissioner, which every state has a process for. For complex or high-value cases, a health law attorney or patient advocate can help. The PSI ACCESS Program offers pro-bono attorneys specifically to help patients navigate insurance denials for medications.
How Medicare Covers IVIG
Medicare Part B covers IVIG for beneficiaries with primary immune deficiency disease, both in clinical settings and at home. To qualify for home IVIG under Medicare, you must be enrolled in Part B under the traditional fee-for-service program (not a Medicare Advantage plan) and have a diagnosis of primary immune deficiency. Standard Part B coinsurance and deductibles apply whether the infusion happens in a doctor’s office, hospital outpatient department, or at home.
If you’re on Medicare and your IVIG is for a condition other than primary immune deficiency, coverage typically falls under the outpatient benefit when administered in a clinical setting. The specific coverage criteria follow CMS’s local coverage determinations, which outline accepted diagnoses including autoimmune blistering diseases, immune thrombocytopenia in pregnancy, and several neurological conditions like Guillain-Barré syndrome and CIDP.
Where You Get the Infusion Matters
Many insurers have site-of-care policies that steer patients away from hospital outpatient departments toward independent infusion centers or home infusion. This matters for coverage because some plans will only approve IVIG at the lowest-cost appropriate setting. A hospital outpatient infusion can cost significantly more than the same treatment at a freestanding infusion center or in your home, and your insurer may deny coverage at the more expensive site or require a higher copay.
Ask your insurance company whether they have a preferred site of care. If home infusion is an option for your condition, it often comes with lower out-of-pocket costs and is more convenient. Your doctor will need to submit a specialty pharmacy referral as part of the prior authorization if home infusion is the plan.
Financial Help Beyond Insurance
Even with insurance approval, IVIG copays and coinsurance can run into thousands of dollars. Several resources exist to bring those costs down.
Pharmaceutical manufacturers offer patient assistance programs for their specific products. CSL Behring provides free product for up to one year for uninsured or underinsured patients prescribed Privigen or Hizentra. Grifols runs the Connexions Program for CIDP patients on Gamunex-C. Shire (now Takeda) has assistance for patients prescribed Gammagard or HYQVIA who lack coverage or have a lapse in insurance. These programs have financial eligibility requirements, so you’ll need to apply.
Nonprofit organizations fill gaps that manufacturer programs don’t cover. Good Days pays insurance copays for qualifying patients on life-sustaining treatments. The HealthWell Foundation assists with copays, deductibles, premiums, and out-of-pocket expenses for chronic conditions. The Patient Advocate Foundation helps with broader access-to-care issues, including employment concerns and financial preservation. NeedyMeds offers a free drug discount card with savings up to 80% at more than 63,000 pharmacies and maintains a database of assistance programs. Your infusion provider or specialty pharmacy can often connect you with the right programs based on your specific situation and insurance type.